Alector advances AL137 toward IND, reports Q2 2026 results
Alector said it selected AL137 as its lead anti-amyloid beta antibody and targets an IND submission in Q1 2027, while reporting $172.8 million in cash as of June 30, 2026.
SEC filing
Latest
Thursday, August 6
Relmada targets year-end IND filings for NDV-01 and sepranolone, reports $217.7M cash
The company said it expects to submit INDs for both lead programs by year-end 2026, with cash it says can fund operations through 2029.
SEC filing
Amphastar hits BAQSIMI sales milestone, triggering $100 million payment to Lilly
The Q2 2026 filing discloses a $100 million payment due to Eli Lilly in Q3 2026 after BAQSIMI sales crossed a contract threshold, alongside new pipeline detail and an April ipratropium bromide launch.
SEC filing
Aclaris reports Q2 2026 results, ATI-052 Phase 1a data and reaffirmed timelines
Aclaris says cash of $170.6 million plus a recent $40.2 million stock sale should fund operations through the end of 2028 as multiple readouts approach.
SEC filing
BioMarin raises 2026 revenue and VOXZOGO guidance, discontinues BMN 401
The company reported 20% revenue growth in Q2 2026, advanced VOXZOGO toward a hypochondroplasia filing, and discontinued BMN 401 after it missed a co-primary endpoint.
SEC filing
Zoetis names Jay Saccaro EVP, CFO and COO, effective August 17, 2026
Wetteny Joseph, the outgoing CFO, will stay on as a special advisor to the CEO through early 2027 under a transition agreement.
SEC filing
HCW Biologics reports $1.6 million private securities sale in SEC filing
The Miramar, Florida biotech disclosed a Regulation D offering with a first sale date of July 29, 2026, sold in full to four investors.
SEC filing
Verastem starts dosing in all three VS-7375 registration trials, secures added $75M financing
The company reported Q2 2026 results alongside new KRAS G12D trial progress and a royalty deal with Oberland Capital that extends its projected cash runway.
SEC filing
Phio reports Q2 2026 results, sets Q3 FDA meeting on PH-762 path
Phio said its Phase 1b skin cancer trial finished in March 2026, with final documentation still in preparation as it plans an FDA meeting in the third quarter.
SEC filing
Puma Biotechnology raises 2026 guidance on NERLYNX demand, details alisertib trial timeline
Puma reported second quarter 2026 results and outlined milestones for its ALISCA alisertib program over the next 12 months while raising full-year revenue and net income guidance.
SEC filing
Relay Therapeutics files to sell up to $213 million more shares via TD Cowen
The prospectus supplement expands Relay's at-the-market equity program after the company had already sold 16 million shares under the original agreement.
SEC filing
Ligand raises EPS guidance floor, closes XOMA Royalty deal, reports pipeline progress
Filspari's FSGS launch, Capvaxive's pediatric expansion, and volixibat's Breakthrough Therapy tag headline a quarter that also saw a $700 million convertible note deal and the XOMA acquisition close.
SEC filing
Ardelyx revises IBSRELA guidance, pulls XPHOZAH long-term outlook amid payor hurdles
Ardelyx reported Q2 2026 revenue growth but cited increased payor utilization management as it updates full-year and long-term projections.
SEC filing
Celldex reports Q2 2026 results as barzolvolimab Phase 3 enrollment finishes early
Celldex says its two pivotal CSU trials completed enrollment ahead of schedule, with topline results due in September or October 2026 ahead of a planned 2027 BLA filing.
SEC filing
Viridian reports Q2 2026 results as Lumvoa launch begins in the U.S.
The FDA-approved thyroid eye disease drug started shipping doses in July, while Viridian keeps a Q1 2027 BLA target for follow-on candidate elegrobart.
SEC filing
Voyager reports Q2 2026 results, sets Q4 milestones for two Alzheimer's programs
The company said tau PET imaging data for VY7523 and dosing initiation for VY1706 are both expected in the fourth quarter of 2026, with cash runway now guided into 2028.
SEC filing
Precision BioSciences reports first biopsy evidence of cccDNA elimination in HBV trial
Q2 2026 update shows liver biopsy proof of viral DNA reduction and sustained pgRNA loss in the ELIMINATE-B trial, as DMD trial sites begin recruiting.
SEC filing
Nuvation Bio posts Q2 2026 results, expands safusidenib program, reports IBTROZI uptake data
The company reported second-quarter revenue driven by IBTROZI sales, disclosed new long-term safusidenib data, and outlined two new studies for the glioma drug.
SEC filing
NextCure reports Q2 2026 results, moves toward Avere Therapeutics merger
NextCure is preserving cash ahead of a planned merger with Avere Therapeutics that includes a roughly $320 million private financing, while winding down its own clinical programs.
SEC filing
vTv Therapeutics reports Q2 2026 results, reaffirms cadisegliatin trial timelines
The company said Phase 3 CATT1 enrollment should finish in the third quarter of 2026, with a related Phase 2a hybrid closed-loop study to begin before year end.
SEC filing
Generate Biomedicines reports Q2 2026 results, advances asthma and oncology pipeline
Phase 3 asthma trials expand recruitment and an oncology combination study completes enrollment as cash falls to $457.4 million.
SEC filing
Roivant reports Q1 fiscal 2027 results, pipeline on track across four vants
Roivant said brepocitinib launch prep for dermatomyositis remains on schedule, three trial readouts are due in the second half of 2026, and it holds $3.9 billion in cash and securities.
SEC filing
Climb Bio reports Q2 2026 results, sets CLYM116 R&D event and Phase 2 start
Climb Bio said it plans to present initial CLYM116 Phase 1 data on September 3, 2026 and expects Phase 2 dosing in IgA nephropathy to begin in the third quarter of 2026, with cash extending into the second half of 2028.
SEC filing
ALX Oncology posts Q2 2026 results, reaffirms mid-2027 ASPEN-09-Breast readout
The company also detailed new HER2-positive breast cancer data, an on-track ALX2004 safety readout, and $153.4 million in cash.
SEC filing
Immunocore posts Q2 KIMMTRAK sales growth as key melanoma trial nears enrollment target
The company said its Phase 3 TEBE-AM trial is nearing its 540-patient enrollment target, with topline data possible by the end of 2026.
SEC filing
Surrozen reports Q2 2026 results, plans SZN-8141 IND filing by Q3 end
The company also targets a year-end 2026 start for its DUET trial in diabetic macular edema, with initial data expected in the second half of 2027.
SEC filing
VivoSim regains Nasdaq equity compliance, discloses post-10-K cash inflows
San Diego based VivoSim said Nasdaq confirmed it meets the $2.5 million stockholders' equity rule, while new milestone cash and a warrant financing lifted its cash position to $10.1 million.
SEC filing
Intellia reports positive Phase 3 HAELO data for lonvo-z, resumes nex-z enrollment
Intellia expects FDA to accept its BLA for lonvo-z in the second half of 2026 and plans a U.S. launch in the first half of 2027, while nex-z Phase 3 enrollment has restarted.
SEC filing
Structure Therapeutics doses first patients in Phase 3 obesity program for aleniglipron
The company started its ACCOMPLISH-1 and -2 trials as it reported second-quarter 2026 results and named a new chief commercial officer.
SEC filing
Halozyme posts record Q2 2026, raises full-year guidance on royalty growth
Five new ENHANZE and Hypercon collaborations signed through July, including deals with Vertex, GSK, Incyte and Oruka, push revenue and EBITDA guidance higher.
SEC filing
IN8bio reports Q2 2026 results, GBM survival data and TCE platform progress
The company disclosed median overall survival exceeding 19.5 months in glioblastoma patients treated with repeat-dosed DeltEx DRI, alongside $18.0 million in cash as of June 30, 2026.
SEC filing
Scholar Rock updates apitegromab BLA progress, starts FSHD Phase 2 trial
The company reported two active fill-finish supply paths for its SMA drug ahead of a September 30 PDUFA date and disclosed $492 million in cash as of June 30, 2026.
SEC filing
Prime Medicine clears path for two liver programs, gains RMAT for PM359
Global Phase 1/2 clearances for Wilson disease and a favorable arbitration outcome with Beam Therapeutics advance Prime Medicine's pipeline as cash runway extends into 2027.
SEC filing
Novavax raises 2026 revenue outlook, flags Sanofi trial talks and C. diff progress
Novavax lifted its full-year revenue framework to $235-$275 million and said Sanofi is in advanced regulatory talks over its combination COVID-flu trial timing.
SEC filing
Zai Lab reports Q2 2026 results, advances zoci and ZL-1503 toward key milestones
The company reported second-quarter revenue of $106.3 million and detailed multiple regulatory and clinical steps across its oncology and immunology pipeline.
SEC filing
Lineage reports Q2 2026 results, advances COR1 corneal program and OpRegen data
Lineage highlighted three-year OpRegen data, early COR1 manufacturing progress, and a new scientific advisory board, with cash seen lasting into Q3 2028.
SEC filing
Corvus reports Q2 2026 results, updates soquelitinib pipeline progress
Corvus reported enrollment progress in its Phase 3 PTCL and Phase 2 atopic dermatitis trials, new hidradenitis suppurativa and asthma studies planned this year, and $215.2 million in cash as of June 30, 2026.
SEC filing
Exelixis registers Phase 3 STELLAR-316 trial of zanzalintinib in colorectal cancer MRD
Compass Therapeutics awaits FDA input on tovecimig biliary cancer data
The company said it expects to hear from the FDA in the third quarter of 2026 on Phase 2/3 results for tovecimig ahead of a possible BLA filing later this year.
SEC filing
QuidelOrtho cuts full-year 2026 guidance on China pricing pressure
The diagnostics maker lowered its 2026 revenue and earnings outlook and pulled its free cash flow guidance, citing slower China sales tied to proposed pricing changes.
SEC filing
Zoetis cuts full-year 2026 guidance as companion animal demand softens
Zoetis reported second-quarter revenue of $2.5 billion and lowered its 2026 revenue and adjusted EPS outlook, citing weaker U.S. companion animal sales.
SEC filing
Immunovant reports Q1 fiscal 2026 results, says IMVT-1402 timelines on track
The company reported cash of $797.8 million as of June 30, 2026, and said all six IMVT-1402 disease programs remain on schedule.
SEC filing
Insmed raises BRINSUPRI guidance and combined peak sales estimate to over $14 billion
Second-quarter 2026 revenue hit $425.5 million as BRINSUPRI sales jumped and Insmed pushed forward regulatory and trial plans for its respiratory pipeline.
SEC filing
Scholar Rock refiles at-the-market offering for up to $200 million
The company superseded its November 2025 sales agreement prospectus, with shares closing at $45.85 on August 3, 2026.
SEC filing
Cryoport supports 779 clinical trials and 22 approved cell and gene therapies as of Q2 2026
The temperature-controlled supply chain provider reported Q2 revenue of $49.0 million and said four customers filed BLA/MAA applications during the quarter, with 11 more expected by year end.
SEC filing
Sanofi posts results across four trials; RSV toddler study OPAL ended early by sponsor decision
Ironwood raises 2026 guidance again as apraglutide trial recruits and debt is repaid
The company lifted full-year LINZESS, revenue, and EBITDA guidance for a second straight quarter while its confirmatory apraglutide trial begins enrolling patients and it retires $200 million in convertible notes.
SEC filing
Amylyx completes LUCIDITY dosing period, sets late-August/early-September readout
Amylyx said the last participant finished the 16-week double-blind portion of the Phase 3 avexitide trial in post-bariatric hypoglycemia, with cash runway into 2028.
SEC filing
Edgewise reports Q2 2026 results, positive Phase 2 HCM data and closed Servier sale
Edgewise plans a Phase 3 HCM trial in Q4 2026 after positive EDG-7500 data, and booked $1.55 billion upfront from its muscular dystrophy business sale to Servier.
SEC filing
Maravai reports Q2 2026 revenue up 8.5%, raises full-year Adjusted EBITDA guidance
Maravai posted $51.4 million in quarterly revenue and narrowed its net loss, while lifting its 2026 Adjusted EBITDA outlook to $33 million to $35 million.
SEC filing